Antibiotic development-déjà vu: Are we facing the "preantibiotic era" again?

Infectious Diseases in Clinical Practice

Volumn 15, Issue 2, 2007, Pages 75-78

  Echols, Roger M ^a   Tillotson, Glenn S ^a   File Jr , Thomas M ^b  

^a Replidyne Inc   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; DAPTOMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; PLACEBO; TELITHROMYCIN;

CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; LUNG DISEASE; PNEUMONIA; RESPIRATORY TRACT INFECTION; SINUSITIS;

EID: 34247106308     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000240866.05059.1a     Document Type: Editorial

References (30)

1. Task Force on Antimicrobial Availability. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews (Infectious Diseases Society of America, Alexandria, VA, July 2004). Available at: http://www.idsociety.org/pa/IDSA_paper4_final_web.pdf. Accessed February 13, 2007.
2. Talbot GH, Bradley J, Edwards JE Jr, et al. Antimicrobial availability task force of the IDSA. Clin Infect Dis. 2006;42:657-668.
3. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273:957-960.
4. Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2:CD004403.
5. Usdin S. FDA's superior attitude. BioCentury. 2006;14:A7-A10.
6. Usdin S. Antibiotic resistance. BioCentury. 2006;14:A1-A6.
7. FDA guidance for antimicrobials. The Division of Anti-Infective Drug Products. "Points to Consider: Clinical Development and Labeling of Anti-Infective Drug Products" October 26, 1992.
8. Usdin S. Science friction. BioCentury. 2006;14:A1-A8.
9. "FDA panel supports Ketek as second-line for CAP: suggests black box," Pink Sheet. January 1, 2007:69, 15-19.
10. Grassley C. Letter to Andrew C von Eschenbach, MD, Acting Commissioner, Food and Drug Administration. Available at: http://www.finance.senate.gov/ sitepages/grassley.htm. Accessed April 27, 2006.
11. Dingell J, Grassley C, Markey E, et al. Letter to David M Walker, Comptroller General of the United States. Available at: http://www.markey.house. gov/docs/health/09-06-06%20letter%20to20GAO.pdf. Accessed September 6, 2006.
12. Available at: http://www.fda.gov/cder/guidance/ptc.htm. Accessed February 13, 2007.
13. Cubicin (daptomycin) prescribing information. Lexington, MA: Cubist Pharmaceuticals; 2004.
14. European Medicines Agency/Committee for Proprietary Medicinal Products. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (EMEA/CPMP, London, October 2004). Available at: http://www.emea.eu.int/index/indexh1.htm. Accessed February 13, 2007.
15. US Food and Drug Administration/Center for Drug Evaluation and Research. Guidance for industry for Special protocol assessment (FDA/CDER, Rockville, MD, 2002). Available at: http://www.fda.gov/cder/guidance/3764fnl.htm. Accessed February 13, 2007.
16. Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2006;144:894-903.
17. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-471.
18. Wilson R. Evidence of bacterial infection in acute exacerbations of chronic bronchitis. Semin Respir Infect. 2000;15:208-215.
19. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608-1613.
20. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-1422.
21. Allegra L, Grassi C, Grossi E, et al. The role of antibiotics in the treatment of chronic bronchitis exacerbation: follow-up of a multicenter study. Ital J Chest Dis. 1991;45(3):138-148.
22. Osborn MK, Steinberg JP. Subdural empyema and other suppurative complications of paranasal sinusitis. Lancet Infect Dis. 2007;7: 62-67.
23. Powers JH. Gemifloxacin (Factive) Anti-Infective Advisory Committee, Bethesda, MD. September 12, 2006.
24. Williams JW Jr, Aguilar C, Cornell J, et al. Antibiotics for acute maxillary sinusitis (review). Cochrane Collaboration, Issue 5, 2005.
25. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol. 2004;114:155-212.
26. Meltzer EO, Weinstein SF, Zitt MJ. Optimal management of community-acquired acute bacterial rhinosinusitis: the allergist perspective. Ann Allergy Asthma Immunol. 2006;96:390-397.
27. Christoffersen R. Antibiotics - an investment worth making? Nat Biotechnol. 2006;24:1512-1514.
28. Bishai W. The in vivo -in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemothe. 2002;49:433-436.
29. Price DB, Honeybourne D, Little P, et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir Med. 2004;98:17-24.
30. Blaser MJ, Bartlett JG. Letter to Acting Commissioner of Food and Drugs Administration. Available at: http://www.idsociety.org/template.cfm?Section= home&template=/contentmanagement/contentdisplay.cfm&contentID=17039. Accessed September 28, 2006.